Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 5, 2012, Pages 511-518

  Graham, Susan M ^a,b,c   Jalalian Lechak, Zahra ^d   Shafi, Juma ^b   Chohan, Vrasha ^a,e   Deya, Ruth W ^b   Jaoko, Walter ^b   Mandaliya, Kishor N ^e   Peshu, Norbert M ^c   Overbaugh, Julie ^d   Mcclelland, R Scott ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d Fred Hutchinson Cancer Research Center   (United States)

^e PathCare ^*  (Kenya)

Author keywords

adherence; antiretroviral therapy; female; HIV drug resistance; virus shedding

Indexed keywords

LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG WITHDRAWAL; FEMALE; FEMALE GENITAL SYSTEM; GENETIC RESISTANCE; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TREATMENT REFUSAL; VAGINA SECRETION; VIRUS LOAD; VIRUS MUTATION; VIRUS SHEDDING; VISUAL ANALOG SCALE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; PLASMA; PROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; VIRUS SHEDDING; WITHHOLDING TREATMENT;

EID: 84864284315     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31825bd703     Document Type: Article

References (28)

1. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2010.
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. (Pubitemid 30432540)
3. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366. (Pubitemid 30182431)
4. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223-231.
5. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI-or PI-treated patients. HIV Clin Trials. 2007;8:282-292. (Pubitemid 350099562)
6. Eron JJ, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS. 1998;12:F181-F189. (Pubitemid 28479268)
7. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-311. (Pubitemid 28366419)
8. Kenya Ministry of Health. Guidelines to Antiretroviral Drug Therapy in Kenya. Nairobi, Kenya: Kenya Ministry of Health; 2001.
9. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100-1102. (Pubitemid 38989377)
10. John GC, Sheppard H, Mbori-Ngacha D, et al. Comparison of techniques for HIV-1 RNA detection and quantitation in cervicovaginal secretions. J Acquir Immune Defic Syndr. 2001;26:170-175. (Pubitemid 32224189)
11. DeVange Panteleeff D, Emery S, Richardson BA, et al. Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples. J Clin Microbiol. 2002;40:3929-3937. (Pubitemid 35285770)
12. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr. 2009;51:522-529.
13. Frenkel LM, McKernan J, Dinh PV, et al. HIV type 1 zidovudine (ZDV) resistance in blood and uterine cervical secretions of pregnant women. AIDS Res Hum Retroviruses. 2006;22:870-873. (Pubitemid 44757163)
14. Graham SM, Masese L, Gitau R, et al. Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis. 2010; 202:1538-1542.
15. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121. (Pubitemid 34289685)
16. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112-1118. (Pubitemid 37323668)
17. von Wyl V, Yerly S, Böni J, et al. Incidence of HIV-1 drug resistance among antiretroviral treatment-naïve individuals starting modern therapy combinations. Clin Infect Dis. 2012;54:131-140.
18. Rosenblum M, Deeks SG, van der Laan M, et al. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One. 2009;4:e7196.
19. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55:460-465.
20. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008;3:e2783.
21. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21:965-971. (Pubitemid 46684328)
22. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS. 2010;5:70-77.
23. Price MA, Wallis CL, Lakhi S, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses. 2011;27:5-12.
24. Hamers RL,Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviralnaive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11:750-759.
25. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012;12:307-317.
26. Jordan M, Kelley K, Saadani Hassani A, et al. Monitoring ART: clinic and program performance using WHO HIV drug resistance early warning indicators in 21 countries. Paper presented at: the 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA. Paper 626.
27. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3:77ra29.
28. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med. 2011;365:493-505.